HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.
The non-interventional study is being led by Dr. Jérôme Benoit, Oncovet's Clinical Director, and will evaluate circulating nucleosomes of dogs and cats with cancer using Volition's Nu.Q® Vet Cancer Test.
Volition's Nu.Q® Vet Cancer Test is a simple, easy-to-use blood test currently available for cancer screening in dogs with ongoing research into its use for cancer screening in cats, and disease monitoring in both species.
Dr. Jérôme Benoit, Clinical Director at Oncovet, said: "Volition's Nu.Q® Vet Cancer Test has already been shown to detect systemic cancers in dogs such as lymphoma and hemangiosarcoma. We will seek to establish whether other common cancers that we regularly see in clinic, could also be detected in dogs and cats by measuring circulating nucleosomes at diagnosis and throughout treatment.
"We are excited to work with the team at Volition, providing samples from 100 dogs and 25 cats with a wide range of cancers, over the coming year. We look forward to supporting Volition as the company expands its operations into Europe, enabling veterinarians and pet owners across the region to benefit from the Nu.Q® Vet Cancer Test."
Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: "We are delighted to collaborate with Dr. Benoit and his team on this research study. Jérôme is highly respected within the veterinary oncology sector and Oncovet is well known in Europe for the design and management of veterinary clinical trials in dogs and cats."
"We are hoping that this initial study will be the start of an effective, long-term relationship with Oncovet, as we seek to broaden the range of cancers that our Nu.Q® Vet Cancer Test can detect across different species. We look forward to sharing the results."
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com.
Note to editors:
Findings from a clinical study conducted by Volition and Professor Wilson-Robles and the team at Texas A&M University, peer-reviewed and published in August 2022, showed that:
- Volition's Nu.Q® Vet Cancer Test detected 76% of systemic cancers ( including lymphoma, hemangiosarcoma, and histiocytic sarcoma) at 97% specificity versus control.
Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.
The contents found at Volition's and Oncovet's website addresses are not incorporated by reference into this document and should not be considered part of this document. Such website addresses are included in this document as inactive textual references only.
Oncovet's mission is to give the best possible welcome and treatment to the patients you entrust us with. Oncovet strives for excellence and relies on the skills of its specialists renowned at European level, as well as on the team supporting them, to offer comprehensive care. Our services include surgery, cardiology, imaging, radiotherapy, medical oncology, and internal medicine. We care for patients who come to us from across Europe. For more information, go to: www.oncovet.fr
Louise Batchelor/Debra Daglish, Volition, firstname.lastname@example.org +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to the potential uses, benefits and effectiveness of its Nucleosomics™ technology platform, including the Nu.Q® Vet Cancer Test, as well as the anticipated benefits of its relationship with Oncovet. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests, a failure by the marketplace to accept Volition's Nu.Q® Vet Cancer Test or other products based on its Nucleosomics™ platform; Volition's failure to secure adequate intellectual property protection; Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition will face fierce competition and its intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Forward-looking statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.